This disclosure relates to the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-l-yl]-methanone. The disclosure also relates to pharmaceutical compositions comprising the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-l-yl]-methanone. The disclosure also relates to methods of treating cancers comprising administering to a patient in need thereof the crystalline fumarate salt of (S)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl] [3-hydroxy-3-(piperidin-2-yl) azetidin-1-yl]-methanone.La presente descripción se refiere a la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4- yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1- il]-metanona. La descripción también se refiere a composiciones farmacéuticas que comprenden la sal de fumarato cristalina de (S) - [3,4-difluoro-2- (2-fluoro-4- yodofenilamino)fenil][3-hidroxi-3- (piperidin-2-il)azetidin-1- il]-metanona. La descripción también se refiere a métodos para tratar cánceres que comprenden administrarle a un paciente que lo necesita la sal de fumarato cristalina de (S)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil ][3- hidroxi-3-(piperidin-2-il)azetidin-l-il]-metanona.
